AHN Cancer Institute - Allegheny General Hospital — Pittsburgh, Pennsylvania

AHN Cancer Institute - Allegheny General Hospital is a clinical research site located in Pittsburgh, Pennsylvania, United States 15212.

Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.

AHN Cancer Institute - Allegheny General Hospital has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: Urothelial Carcinoma, Metastatic Pancreatic Cancer.

Sponsors: Seagen, a wholly owned subsidiary of Pfizer, Cantex Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for AHN Cancer Institute - Allegheny General Hospital?

AHN Cancer Institute - Allegheny General Hospital has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has AHN Cancer Institute - Allegheny General Hospital conducted?

AHN Cancer Institute - Allegheny General Hospital has 2 clinical trials on record, with 2 currently active. Their work covers Urothelial Carcinoma, Metastatic Pancreatic Cancer.

Is AHN Cancer Institute - Allegheny General Hospital accredited by Crixeo Health?

AHN Cancer Institute - Allegheny General Hospital has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about AHN Cancer Institute - Allegheny General Hospital?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.